Overview

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links Corporate Governance Annual Reports Quarterly Reports 2010 Annual Meeting Materials Receive E-mail Alerts Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!

MNKD (Common Stock) Exchange NASDAQ GM (US Dollar) Price $2.17 Change (%) 0.00 (0.00%) Volume 0 Data as of 02/03/12 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Date Title   02/02/12 MannKind Receives Commitment from The Mann Group to Acquire 31,250,000 Shares of Common Stock VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 2, 2012-- MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into a purchase agreement with The Mann Group LLC, an entity controlled by MannKind’s chief executive officer and principal stockholder, Alfred E. Mann, for the sale of shares of its common stock to The Mann Group. The Mann Group has committed to purchase 31,250,000 restricted shares of MannKind’s common stock, the same number of ...  02/02/12 MannKind Announces Pricing of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 2, 2012-- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of an underwritten public offering of 31,250,000 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.6 of a share of its common stock. The shares of common stock and the warrants are being offered at a combined price to the public of $2.40 per unit. The gross proceeds to MannKind from this offerin...  01/31/12 MannKind Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 31, 2012-- MannKind Corporation (Nasdaq: MNKD) today announced that it intends to offer and sell, subject to market and other conditions, $50 million worth of units in an underwritten public offering, with each unit consisting of one share of MannKind’s common stock and a warrant to purchase 0.6 of a share of MannKind’s common stock. MannKind also intends to grant to the underwriters of the offering an option t...  01/05/12 MannKind to Present at 30th Annual J.P. Morgan Healthcare Conference VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 5, 2012-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 30th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2012 at 8:00 am (PT) at the Westin St. Francis Hotel in San Francisco, California. Interested parties can access a link to the live webcast of the ...

Print |  E-mail Page |  RSS Feeds |  E-mail Alerts |  IR Contacts |  Tear Sheet